Pro-life CEO predicts Trump FDA nominee could bring renewed scrutiny to abortion drug risks

Trump's FDA nominee Heidi Overton could face questions about mifepristone regulation, according to Catherine Glenn Foster, president of Americans United for Life, who stated the nominee aligns with pro-life positions. Overton has not made public statements about mifepristone policy. The FDA approved mifepristone in 2000 and has maintained its approval through subsequent reviews.

Next story